Ginger Sue Carmichael

Ginger Carmichael practices at Mission Hope Infusion Center - HOPD in Santa Maria, California.

Ginger Carmichael's NPI, 1760974018, was assigned on June 2, 2018. Ginger Carmichael holds California license 95016420.

Ginger Carmichael's primary practice is Mission Hope Infusion Center - HOPD, at 1325 Church St, STE 201, Santa Maria, CA 93454.

Ginger Carmichael's primary practice is Mission Hope Infusion Center - HOPD in Santa Maria, California. Ginger Carmichael is also affiliated with Dignity Health - Marian Regional Medical Center. The medical group on file is Pacific Central Coast Health Centers Medical Group. Dmand AI also links Ginger Carmichael to 1 more group practice or clinic and 1 hospital outpatient department, each named with a free account. Ginger Carmichael's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Ginger Carmichael practices, 4 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Ginger Carmichael's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Dmand AI has Ginger Carmichael's licenses on file in 2 states: California and Colorado.

Dmand AI lists contact dermatitis among the conditions Ginger Carmichael treats.

CMS data shows 604 Medicare services from Ginger Carmichael across 2 procedure codes in 2024, all of them office visits, for 322 Medicare patients. Medicare paid $62,751 for them. Every service was in an office.

CMS counts 322 Medicare patients who saw Ginger Carmichael in 2026. The largest group is 65 to 74, with 136 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Ginger Carmichael's median patient age at 71, with 63% women.

In 2026, Ginger Carmichael wrote 510 Medicare Part D claims for 148 patients. 94% of them were for generic drugs. CMS names the drug for 388 of them, across 11 drugs with 11 or more claims each, at $6,053 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Ginger Carmichael for performance year 2026, reported through an alternative payment model (APM). Ginger Carmichael accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Ginger Carmichael as offering telehealth.

CMS Open Payments shows 12 general payments to Ginger Carmichael from 5 drug and device companies from 2024 to 2025. Education make up the largest share, 90% of the total. Astellas Pharma US Inc paid the most, $758.